Challenges of Urinary Tract Infections and New Treatment Options

Urinary tract infections, or UTIs, are notoriously uncomfortable. If you’ve ever had one, you know the constant urge to urinate, even right after going, not to mention the burning pain and cloudy urine. They’re surprisingly common, really—over 50% of women experience at least one UTI in their lifetime. And, unfortunately, they can recur fairly quickly. What’s adding to the frustration is that treating these infections has become more complicated due to a rise in antibiotic-resistant UTIs. Simply put, many standard drugs aren’t as effective anymore.

Dr. Cynthia DeTata, an ob-gyn at Stanford Medicine, points out that these infections aren’t just unpleasant; they’re becoming harder to treat. The primary reason for this resistance is often improper use of antibiotics, like not completing the full course. “If the treatment is incomplete, bacteria can bounce back, sometimes even stronger,” she explains.

Currently, experts see an urgent need for effective new treatments to manage UTIs effectively. Dr. Gil Weiss, another ob-gyn, mentions that the last new antibiotic for uncomplicated UTIs was approved three decades ago, while bacteria have continued to adapt and evolve. It feels a bit stagnant, doesn’t it?

Here’s some good news, though: there’s a newly approved antibiotic called gepotidacin (marketed as Blujepa), offering doctors a fresh weapon against these stubborn infections. It’s significant because it’s the first new class of antibiotics to emerge since the 1990s, and experts believe it may carry a lower risk of developing resistance.

To break it down, while there are effective treatments for UTIs, the growing antibiotic resistance complicates matters. UTIs impact up to 16 million women each year in the U.S., with 30 to 44% of them experiencing recurring infections within just months. Studies show that 92% of bacteria involved in UTIs are resistant to at least one antibiotic, with nearly 80% not responding to two or more antibiotics.

In a glimmer of hope, the FDA approved gepotidacin for treating uncomplicated UTIs in March 2025. While other antibiotics like Pivya and Orlynvah had been approved in 2024, they were part of existing classes. “Gepotidacin represents a completely new class of antibiotics, known as triazaacenaphthylenes,” DeTata mentions. “Currently, it’s the sole member of its class.”

So, how does it work? Antibiotics generally fight bacteria by either killing them outright or stopping them from multiplying. For example, some disrupt bacterial cell walls, leading to their death, while others prevent protein synthesis. Gepotidacin, however, operates differently by targeting enzymes called topoisomerases, breaking the DNA strands of bacteria, effectively killing them in the process.

In clinical trials, common side effects included diarrhea (not exactly surprising for antibiotics) in about 16% of participants and nausea in 9%. Notably, gepotidacin performed on par with or even better than nitrofurantoin, which is often the go-to treatment for UTIs.

Interestingly, there’s also potential for gepotidacin to be effective against gonorrhea—another infection that has become challenging due to antibiotic resistance. This just adds another layer to its significance.

For Dr. Weiss and others, a new treatment option for UTIs is certainly something to celebrate. “Having a new medication available is a big deal,” he expresses. “Any new option for something so prevalent is definitely a positive step.”